Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

K. Kolibaba · SciRah

Researcher profile · Semantic Scholar

K. Kolibaba

Share profile

K. Kolibaba — researcher profile on SciRah

h-index: 25
Works: 92
Citations: 4,715

Most-cited papers

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
R. Advani, J. Buggy, J. Sharman, Sonali M. Smith +11 more
2013Journal of Clinical Oncology1,116 citations Open access
Semantic Scholar
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.
I. Flinn, R. van der Jagt, B. Kahl, P. Wood +13 more
2014Blood639 citations Open access
Semantic Scholar
Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells.
J. T. Thiesing, Sayuri Ohno-Jones, K. Kolibaba, Brian J. Druker
2000Blood332 citations
Semantic Scholar
Protein tyrosine kinases and cancer.
K. Kolibaba, B. Druker
1997Biochimica et Biophysica Acta289 citations
Semantic Scholar
First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study.
I. Flinn, R. van der Jagt, B. Kahl, P. Wood +10 more
2019Journal of Clinical Oncology237 citations Open access
Semantic Scholar
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS).
F. Morschhauser, I. Flinn, R. Advani, L. Sehn +19 more
2019The Lancet Haematology221 citations Open access
Semantic Scholar
An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia.
J. Sharman, M. Hawkins, K. Kolibaba, M. Boxer +5 more
2015Blood180 citations Open access
Semantic Scholar
Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
J. Leonard, K. Kolibaba, J. Reeves, A. Tulpule +17 more
2017Journal of Clinical Oncology150 citations
Semantic Scholar
Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study.
H. Tilly, F. Morschhauser, N. Bartlett, A. Mehta +11 more
2019The Lancet Oncology117 citations Open access
Semantic Scholar
Direct binding of CRKL to BCR-ABL is not required for BCR-ABL transformation.
Conor Heaney, K. Kolibaba, Arun Bhat, Tsukasa Oda +3 more
1997Blood88 citations
Semantic Scholar
Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma.
N. Dibella, R. Taetle, K. Kolibaba, T. Boyd +12 more
2008Blood81 citations
Semantic Scholar
Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia.
J. Byrd, J. Flynn, T. Kipps, M. Boxer +6 more
2016Blood80 citations Open access
Semantic Scholar
Interactions of CBL with BCR-ABL and CRKL in BCR-ABL-transformed Myeloid Cells*
Arun Bhat, K. Kolibaba, Tsukasa Oda, Sayuri Ohno-Jones +2 more
1997Journal of Biological Chemistry69 citations Open access
Semantic Scholar
A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma
T. Phillips, P. Barr, Steven I. Park, K. Kolibaba +10 more
2018Investigational new drugs68 citations Open access
Semantic Scholar
Ublituximab (TG‐1101), a novel glycoengineered anti‐CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial
J. Sharman, C. Farber, D. Mahadevan, M. Schreeder +9 more
2016British Journal of Haematology59 citations Open access
Semantic Scholar
The Btk Inhibitor, PCI-32765, Induces Durable Responses with Minimal Toxicity In Patients with Relapsed/Refractory B-Cell Malignancies: Results From a Phase I Study
N. Fowler, J. Sharman, Sonali M. Smith, T. Boyd +7 more
201059 citations
Semantic Scholar
Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study
J. Gribben, W. Jurczak, R. Jacobs, S. Grosicki +23 more
2020Blood56 citations Open access
Semantic Scholar
Extended dosing with CC‐486 (oral azacitidine) in patients with myeloid malignancies
M. Savona, K. Kolibaba, P. Conkling, E. Kingsley +8 more
2018American journal of hematology/oncology56 citations Open access
Semantic Scholar
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
J. Sharman, D. Brander, A. Mato, N. Ghosh +15 more
2021The Lancet Haematology45 citations
Semantic Scholar
An open‐label phase 2 trial of entospletinib in indolent non‐Hodgkin lymphoma and mantle cell lymphoma
D. Andorsky, K. Kolibaba, S. Assouline, A. Forero-Torres +8 more
2018British Journal of Haematology43 citations Open access
Semantic Scholar
Effect of Btk inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase I study.
R. Advani, J. Sharman, Sonali M. Smith, D. Pollyea +6 more
201039 citations
Semantic Scholar
Updated Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
F. Morschhauser, I. Flinn, R. Advani, C. Diefenbach +17 more
201438 citations
Semantic Scholar
Randomized Phase 2 Open-Label Study of R-CHOP ± Bortezomib in Patients (Pts) With Untreated Non-Germinal Center B-Cell-like (Non-GCB) Subtype Diffuse Large Cell Lymphoma (DLBCL): Results From the Pyramid Trial (NCT00931918).
J. Leonard, K. Kolibaba, J. Reeves, A. Tulpule +16 more
2015Clinical advances in hematology & oncology : H&O35 citations
Semantic Scholar
Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma
M. Khasraw, M. Weller, D. Lorente, K. Kolibaba +12 more
2021Neuro-Oncology Advances34 citations Open access
Semantic Scholar
Obinutuzumab (GA101) 1,000 mg versus 2,000 mg in patients with chronic lymphocytic leukemia (CLL): Results of the phase II GAGE (GAO4768g) trial.
J. Flynn, J. Byrd, T. Kipps, M. Boxer +4 more
201430 citations
Semantic Scholar
Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib Is Highly Active in Patients with Relapsed and/or Refractory Mantle Cell Lymphoma; Results of a Phase II Trial
J. Sharman, C. Farber, D. Mahadevan, M. Schreeder +8 more
201425 citations
Semantic Scholar
Phase I Study of Alvocidib Followed by 7+3 (Cytarabine + Daunorubicin) in Newly Diagnosed Acute Myeloid Leukemia
J. Zeidner, D. Lee, M. Frattini, G. Fine +5 more
2020Clinical Cancer Research24 citations
Semantic Scholar
Assessment of Maintenance Rituximab after First-Line Bendamustine-Rituximab in Patients with Follicular Lymphoma: An Analysis from the BRIGHT Trial
B. Kahl, J. Burke, R. van der Jagt, Julie E. Chang +10 more
201724 citations
Semantic Scholar
Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin (PoV) or pinatuzumab vedotin (PiV) plus rituximab (RTX) in patients (Pts) with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL).
F. Morschhauser, I. Flinn, R. Advani, L. Sehn +16 more
201423 citations
Semantic Scholar
Phase IIIb randomized study of lenalidomide plus rituximab (R2) followed by maintenance in relapsed/refractory NHL: Analysis of patients with double-refractory or early relapsed follicular lymphoma (FL).
D. Andorsky, A. Yacoub, J. Melear, M. Coleman +11 more
201722 citations
Semantic Scholar
Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma.
J. Burke, R. van der Jagt, B. Kahl, P. Wood +10 more
2016Clinical Lymphoma, Myeloma & Leukemia22 citations Open access
Semantic Scholar
Two doses of polatuzumab vedotin (PoV, anti-CD79b antibody-drug conjugate) in patients (pts) with relapsed/refractory (RR) follicular lymphoma (FL): Durable responses at lower dose level.
R. Advani, I. Flinn, J. Sharman, C. Diefenbach +16 more
201522 citations
Semantic Scholar
MAGNIFY: Phase IIIb interim analysis of induction R2 followed by maintenance in relapsed/refractory indolent non-Hodgkin lymphoma.
D. Andorsky, M. Coleman, A. Yacoub, J. Melear +9 more
2019Journal of Clinical Oncology21 citations
Semantic Scholar
Brentuximab Vedotin in Combination with RCHOP As Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study
C. Yasenchak, C. Farber, L. Budde, S. Ansell +10 more
201419 citations
Semantic Scholar
Therapeutic Advances in Hematology
K. Kolibaba, J. Sterchele, A. Joshi, M. Forsyth +3 more
201318 citations
Semantic Scholar
Catalytic domains of tyrosine kinases determine the phosphorylation sites within c‐Cbl
A. Grossmann, K. Kolibaba, S. Willis, A. Corbin +3 more
2004FEBS Letters18 citations Open access
Semantic Scholar
Phase 2 Trial of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Indolent Non-Hodgkin's Lymphoma (iNHL)
J. Sharman, L. Klein, M. Boxer, K. Kolibaba +5 more
201517 citations
Semantic Scholar
Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase Ib/II Study
H. Tilly, F. Morschhauser, N. Bartlett, J. Sharman +8 more
201615 citations
Semantic Scholar
Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: Results of the GENUINE phase 3 study.
J. Sharman, D. Brander, A. Mato, S. Kambhampati +14 more
201714 citations
Semantic Scholar
Phase 1/2 trial of acalabrutinib plus pembrolizumab (Pem) in relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).
T. Witzig, K. Maddocks, S. de Vos, R. Lyons +13 more
2019Journal of Clinical Oncology13 citations
Semantic Scholar
First-line treatment of iNHL or MCL patients with BR or R-CHOP/R-CVP: Results of the BRIGHT 5-year follow-up study.
I. Flinn, R. van der Jagt, Julie E. Chang, P. Wood +9 more
201713 citations
Semantic Scholar
Results of an Ongoing Phase 2 Study of Brentuximab Vedotin with Rchp As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL)
L. Budde, A. Halwani, C. Yasenchak, C. Farber +19 more
201613 citations Open access
Semantic Scholar
Brentuximab Vedotin with RCHOP As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL): Results from an Ongoing Phase 2 Study
C. Yasenchak, A. Halwani, R. Advani, S. Ansell +13 more
201512 citations
Semantic Scholar
Completed Induction Phase Analysis of Magnify: Phase 3b Study of Lenalidomide + Rituximab (R 2) Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
F. Lansigan, D. Andorsky, M. Coleman, A. Yacoub +10 more
2021Blood11 citations Open access
Semantic Scholar
Umbralisib monotherapy demonstrates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: A multicenter, open label, registration directed phase II study.
N. Fowler, F. Samaniego, W. Jurczak, E. Lech-Maranda +16 more
2019Journal of Clinical Oncology11 citations
Semantic Scholar
Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib Dose-Escalation
N. Bartlett, Andy I. Chen, K. Kolibaba, T. Lamy +3 more
201511 citations
Semantic Scholar
CC-486 (Oral Azacitidine) Monotherapy in Patients with Acute Myeloid Leukemia (AML)
M. Savona, S. Gore, K. Kolibaba, S. Ukrainskyj +5 more
201511 citations Open access
Semantic Scholar
Phase 2 Trial Of GS-9973, a Selective Syk Inhibitor, In Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL)
J. Sharman, L. Klein, M. Boxer, K. Kolibaba +7 more
201311 citations
Semantic Scholar
CAM Kinase IV Regulates Lineage Commitment and Survival of Erythroid Progenitors in a Non-Cell–Autonomous Manner
G. Wayman, Melinda J. Walters, K. Kolibaba, T. Soderling +1 more
2000Journal of Cell Biology11 citations Open access
Semantic Scholar
Demographics, treatment patterns, safety, and real-world effectiveness in patients aged 70 years and over with chronic lymphocytic leukemia receiving bendamustine with or without rituximab: a retrospective study
K. Kolibaba, J. Sterchele, A. Joshi, M. Forsyth +3 more
2013Therapeutic Advances in Hematology10 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. Sharman×26
Invite
J. Sharman — researcher profile on SciRah
I. Flinn×14
Invite
I. Flinn — researcher profile on SciRah
J. Burke×12
Invite
J. Burke — researcher profile on SciRah
R. Advani×9
Invite
R. Advani — researcher profile on SciRah

×7

Invite

Andy I. Chen — researcher profile on SciRah

Invite

L. Klein — researcher profile on SciRah

C. Yasenchak×7

Invite

C. Yasenchak — researcher profile on SciRah

F. Morschhauser×6

Invite

F. Morschhauser — researcher profile on SciRah

Invite

G. Salles — researcher profile on SciRah

Invite

H. Tilly — researcher profile on SciRah

Invite

J. Hirata — researcher profile on SciRah

Invite

N. Bartlett — researcher profile on SciRah